Cellectar Biosciences (CLRB) Cash from Financing Activities (2010 - 2025)

Cellectar Biosciences has reported Cash from Financing Activities for 15 years, with the latest figure at $5.0 million in Q4 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $5.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.3 million (down 53.85% YoY) and the FY2025 annual result came in at $13.0 million, down 78.78% from the prior year.
• Cash from Financing Activities slipped to $5.0 million in Q4 2025 per CLRB's latest filing, from $5.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $43.8 million in Q1 2024 and troughed at -$1.0 in Q4 2021.
• A 4-year average of $8.8 million and a median of $1.2 million in 2021 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2024: Cash from Financing Activities slumped 100.0% in 2021, then soared 1461648800.0% in 2024.
• Over 4 years, Cash from Financing Activities stood at -$1.0 in 2021, then soared by 44100200.0% to $441001.0 in 2023, then jumped by 3882.16% to $17.6 million in 2024, then sank by 71.58% to $5.0 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $5.0 million, $5.8 million, and $17.6 million for Q4 2025, Q3 2025, and Q3 2024 respectively.